BTIG Research Issues Positive Forecast for Arvinas (NASDAQ:ARVN) Stock Price

Arvinas (NASDAQ:ARVN) had its price objective lifted by BTIG Research from $14.00 to $16.00 in a research note released on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts have also recently commented on ARVN. Barclays raised their price objective on Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Piper Sandler reaffirmed an “overweight” rating and set a $20.00 target price (up from $16.00) on shares of Arvinas in a research report on Wednesday, February 25th. Wedbush increased their target price on Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th. Truist Financial set a $10.00 price target on shares of Arvinas in a research report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arvinas in a research note on Monday, December 22nd. Ten analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Arvinas has an average rating of “Hold” and an average target price of $13.88.

Arvinas Trading Up 2.6%

ARVN stock opened at $11.17 on Thursday. The stock has a 50-day moving average price of $12.72 and a 200-day moving average price of $11.13. Arvinas has a 1-year low of $5.90 and a 1-year high of $14.51. The firm has a market cap of $714.43 million, a PE ratio of -8.73 and a beta of 1.87.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.55). The business had revenue of $9.50 million for the quarter, compared to the consensus estimate of $37.26 million. Arvinas had a negative net margin of 30.77% and a negative return on equity of 14.25%. The firm’s revenue for the quarter was down 84.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.63) EPS. On average, analysts forecast that Arvinas will post -3.81 earnings per share for the current year.

Insider Activity

In other Arvinas news, CEO Randy Teel sold 4,786 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $12.16, for a total value of $58,197.76. Following the completion of the sale, the chief executive officer directly owned 149,696 shares of the company’s stock, valued at $1,820,303.36. This trade represents a 3.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Noah Berkowitz sold 6,435 shares of Arvinas stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $11.10, for a total value of $71,428.50. Following the completion of the sale, the insider directly owned 202,503 shares of the company’s stock, valued at approximately $2,247,783.30. This trade represents a 3.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 63,864 shares of company stock worth $802,443. 4.73% of the stock is owned by insiders.

Institutional Trading of Arvinas

Institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC lifted its holdings in shares of Arvinas by 491.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after buying an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board grew its stake in Arvinas by 109.4% during the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after acquiring an additional 3,500 shares in the last quarter. State of Wyoming purchased a new position in Arvinas during the third quarter valued at approximately $68,000. Virtus Investment Advisers LLC increased its holdings in Arvinas by 49.3% during the 2nd quarter. Virtus Investment Advisers LLC now owns 12,422 shares of the company’s stock worth $91,000 after acquiring an additional 4,104 shares during the period. Finally, Aster Capital Management DIFC Ltd bought a new stake in Arvinas during the 3rd quarter worth approximately $92,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas News Summary

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Positive Phase 1 data for ARV-102 showed >50% LRRK2 degradation in CSF after 28 days and reductions in endolysosomal and neuroinflammatory biomarkers—data that de‑risks the Parkinson’s program and increases the drug’s clinical value. Arvinas Announces Positive Phase 1 Data for ARV-102
• Positive Sentiment: Citigroup raised its price target from $18 to $21 and initiated/maintained a Buy rating—an analyst upgrade that implies a large upside and can attract momentum investors. Benzinga
• Positive Sentiment: BTIG bumped its target from $14 to $16 and keeps a Buy rating, providing additional brokerage support for the shares and reinforcing the sentiment shift after the clinical news. Benzinga
• Neutral Sentiment: Short-interest reports for mid‑March show anomalous zero/NaN values and a 0.0 days-to-cover figure—data appears unreliable or miscoded and currently offers no clear sign of increased short pressure. Investors should watch for corrected filings for a clearer picture. TipRanks / Short Interest Note

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.